Kornimate/medical-research-clean huggingface dataset:
differential diagnosis between parkinson's disease and multiple system atrophy using digital speech analysis

Conditions: Parkinson Disease; MSA - Multiple System Atrophy

Summary: parkinson's disease (pd) is the second most common neurodegenerative disease. multiple system atrophy (msa) is a relentlessly progressing rare neurodegenerative disease of unknown etiology. in early stages of the disease, pd and msa symptoms are very similar, particularly msa-p where parkinsonism predominates. the differential diagnosis between msa-p and pd can be very challenging in early disease stages, while early diagnostic certitude is important for the patient because of the diverging prognosis. voice disorders are a common early symptom in both diseases and of different origin. the ambition and the originality of this project are to develop a digital voice-based tool for objective discrimination between pd and msa-p.

given the clinical similarity between pd and msa-p in early disease stages and the severity of the prognosis of msa-p, it would be very useful to have objective tools to assist in the differential diagnosis between both disorders. since dysarthria is a common early symptom in both diseases and of different origin, the innovative goal of this project is to use dysarthria, through a digital processing of voice recordings of patients, as a vehicle to distinguish between pd and msa-p in early disease stages. the team will build a corpus of voice samples of patients with both diseases and a recent diagnosis (less than 4 years) and controls. this corpus will consist in sustained vowels, utterances of a standard text and spontaneous speech. the recordings will be performed using a high quality digital recorder (h4n) and the diana and eva-2 workstations. diana is a state-of-the-art system dedicated to pathological voice recording and analysis. an electroglottograph (egg), a non-invasive device, will be also used in conjunction with the recordings to provide the ground truth of glottal opening and closure instants during utterances. the use of an egg can be very useful given that ogi and gci provide valuable information about the voice short-time dynamics.

Eligibility criteria:
inclusion criteria: * patient with parkinson's disease : * diagnosis of idiopathic parkinson's disease (pd) according to criteria (hughes et coll., 1992) * patient in early stage of pd : hoehn\&yahr stage between 1 and 2, and the onset of symptoms ≤ 4 years * patient with or without mild to moderate speech troubles: updrs iii item 18 ≤ 2 * patients with msa-p (parkinsonian form) : * diagnosis of multiple atrophy system (msa) parkinsonian form possible or probable according to gilman et coll 's criteria (2008) * patient in early stage of msa-p: score of part iv of the umsars (unified multiple system atrophy rating scale) ≤ 3 points and the onset of symptoms ≤ 4 years * patient with or without mild to moderate speech troubles: umsars ii item 2 ≤ 2 * controls : * absence of neurologic and oto-rhino-laryngologic disease exclusion criteria: * the deaf and/or mutes * patient with speech troubles which are not related to the msa or pd * person under safeguard justice, guardianship
study on indomethacin-responsive headaches

Conditions: Headache, Migraine

Summary: description of modalities concerning the patient care of headaches sensible to indometacine.

description of clinical profile, treatment of crisis and background treatment

Eligibility criteria:
inclusion criteria: * patient with a diagnosis of migraine with or without aura, or trigemino-autosomic headaches or other primary headaches * patient who are taking indometacine * patient with written consent form exclusion criteria: * patient under 18 years * pregnant woman or breastfeeding patient * patient who refuses to participate
a study of the role of circulating tumor dna in predicting the likelihood of organ preservation after clinical complete response to neoadjuvant therapy for rectal cancer

Conditions: Gastrointestinal Malignancies

Summary: in this research study, the investigators are looking to see if the circulating tumor dna (genetic material), also known as ctdna, in the blood will help them predict whether the participant's cancer will come back.

in this research study, the investigator are performing blood draws to see if the presence or absence of circulating tumor dna (ctdna), the genetic material in the participant's cancer's cells, will help the investigators predict whether the participant's cancer will come back or not.

Eligibility criteria:
inclusion criteria: * participants must have achieved a clinical complete response (ccr) within 3 months of last therapy - defined as absence of residual ulceration, mass or mucosal irregularity at endoscopic assessment - following neoadjuvant therapy with chemoradiation or chemotherapy followed by radiation for stage i, ii, or iii non-metastatic rectal cancer. (whitening of the mucosa with presence of telangiectasia will be accepted as ccr.) * participants must have original tumor tissue (formalin-fixed, paraffin-embedded specimens) available for analysis * participants must be 18 years of age or older. * participants must be able to understand and willing to sign a written informed consent document. * participants must have received long course chemoradiation to 40-54 gy. * participants must have received at least 4 cycles of folfox * participant must be no more than 3 months past the conclusion of initial chemoradiation of rectal cancer (i.e., end of chemoradiation). exclusion criteria: * participants may not have any other organ cancer evident at the time of enrollment. * participants may not have any other concurrent serious illness that makes participation on this study impractical or clinically inappropriate.

Keywords: gastrointestinal malignancies
real-world outcome of psoriasis subjects in korea on adalimumab

Conditions: Psoriasis

Summary: the objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with psoriasis in korea.


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of psoriasis by investigator. * participant (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label. * participant must be able and willing to provide written informed consent and comply with the requirements of this study protocol. exclusion criteria: * participants who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks. * participation in any psoriasis-related clinical trial at the time of enrolment, at baseline or at any point during the study period. * participants, who in the investigator's view, may not be able to accurately report their questionnaires

Keywords: psoriasis adalimumab humira korea
patient self-sampling of hpv to screen for cervical cancer

Conditions: Human Papilloma Virus

Summary: the purpose of this study is to validate a patient self-sampling vaginal collection kit and laboratory testing for the detection of hpv (human papillomavirus) infection. researchers will compare the laboratory results of self-collected vaginal swab samples to usual healthcare provider-collected cervical swab samples to determine the laboratory hpv testing accuracy of the self-collection swab.


Eligibility criteria:
inclusion criteria: * appointment at mayo clinic rochester in gynecology colposcopy clinic or ics (integrated community specialty) colposcopy clinic (will always include a speculum exam). * appointment at mayo clinic rochester in gynecology clinic for indication that will already include a speculum exam (e.g., cervical cancer screening or iud insertion). exclusion criteria: * excluded if self-reported as currently menstruating, pregnant, or within 3 months following pregnancy. * excluded if no cervix (history of total hysterectomy). * excluded if moderate to heavy vaginal bleeding on the day of the visit. * excluded if reason for visit in gynecology clinic is abnormal vaginal discharge. * exclude patients who are on gynecology colposcopy clinic for leep (loop electrosurgical excision procedure). * exclude if any use of over-the-counter or prescription vaginal cream for vaginal infection or prescription vaginal estrogen cream for at least two days before using the evalyn brush. (vaginal contraceptives, condoms and water-based lubricants can be used as normal.)

Keywords: cervical cancer screening
simultaneous recordings of cervical and ocular vestibular-evoked myogenic potentials

Conditions: Vestibular Function Disorder

Summary: to lower the threshold for clinical application by reducing the testing time for recording vestibular-evoked myogenic potentials (vemps), we evaluated whether a simultaneous recording of ocular and cervical vemps after unilateral or bilateral stimulation can be achieved without a loss in diagnostic sensitivity.

the combined evaluation of ocular and cervical vemps permits the assessment of both endorgans and whole vestibular nerve function, as well as the ascending and descending vestibular pathways in the brainstem at once. in about 30 healthy participants and 20 patients with acute unilateral vestibular neuritis, unilateral simultaneous cvemp and ovemp recordings in each side during monaural stimulation (air-conducted sound, 500hz tone bursts, 100 nhl), and bilateral simultaneous recordings of each vemp while binaural stimulation were compared to the conventional method of sequential recording each vemps on each side at a time.

Eligibility criteria:
inclusion criteria: 1. acute onset of vertigo 2. the appearance of mixed horizontal and torsional nystagmus 3. impaired horizontal semicircular canal (scc) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score \> 25%) 4. intact inferior division of vestibular nerve as evidenced by normal cvemp and normal head-impulse test for vertical sccs 5. the absence of auditory and neurologic signs exclusion criteria: * a previous history of vertigo or neuro-otologic diseases

Keywords: vestibular evoked myogenic potentials
effects of very low calorie diet vs metabolic surgery on weight loss and obesity comorbidities

Conditions: Obesity, Morbid; Obesity; Diet, Healthy; Bariatric Surgery Candidate

Summary: it is a prospective randomized trial on 218 subjects, 109 for each arms. the purpose of this trial is to compare very low calorie diet and metabolic surgery induced weight loss and its maintenance.

obesity is a leading public health issued associated with poor quality of life, morbidity and an increased mortality rate. although metabolic surgery results in a greater weight loss when compared to non-surgical approaches, a low calorie diet associated with intensive maintenance session may be a valid alternative for weight loss. since lifestyle interventions are safer and potentially more cost effective than metabolic surgery, this trial will test whether an intensive lifestyle intervention is as effective as metabolic surgery to induce weight loss and its maintenance. a total of 218 participants will be randomly assigned to metabolic surgery (109) or intensive lifestyle intervention (109). clinical outcomes will be assessed at 25% reduction in body mass index (bmi), at 12 months and 24 months.

Eligibility criteria:
inclusion criteria: * aged between 19 and 69 years * body mass index ≥35 kg/m2 and at least one or more obesity-related co-morbidities such as type ii diabetes (t2dm), hypertension, sleep apnea and other respiratory disorders, non-alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease * body mass index ≥40 kg/m2 exclusion criteria: * pregnancy * active cancer * end stage renal failure * end stage liver failure * being unable to understand and sign informed consent
comparative effectiveness study of spironolactone versus doxycycline for acne

Conditions: Acne

Summary: acne is common illness of adolescents and young adults which is associated with substantial morbidity. while topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolactone, and isotretinoin. sebum overproduction is fundamental to the pathogenesis of acne with associated disordered keratinization and subsequent microbial colonization and inflammation resulting in the clinical manifestations of acne. given the influence of hormones on sebum production, therapies that address these underlying hormonal factors such as spironolactone and oral contraceptive pills represent an underutilized treatment option for women with acne and could help decrease the use of long-term oral antibiotics in this patient population. the purpose of this trial is to evaluate the comparative effectiveness of spironolactone versus doxycycline hyclate (tetracycline class antibiotic) for women with acne.


Eligibility criteria:
inclusion criteria: * female sex assigned at birth * age 16-40 years old * acne defined as at least 10 inflammatory papules or pustules and an investigator's global assessment (iga) score of at least 2 as measured by the comprehensive acne severity scale * not currently pregnant or planning to become pregnant exclusion criteria: * pregnancy * heart disease * renal disease * liver disease * orthostatic hypotension * addison's disease * history of hyperkalemia * allergy to tetracycline-class antibiotic * allergy to spironolactone * concomitant use of medications known to interact with spironolactone or doxycycline or that may increase the risk for hyperkalemia, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, eplerenone, nonsteroidal anti-inflammatory drugs, and digoxin. * treatment with spironolactone, an oral antibiotic, laser, photodynamic therapy, or chemical peel within the past 4 weeks * treatment with isotretinoin within the past 3 months * sebacia laser treatment within the past 12 months

Keywords: spironolactone doxycycline
heat application to quadriceps effect on pain after a total knee arthroplasty

Conditions: Arthritis Knee

Summary: the goal of this study is to explore an under-researched aspect of recovery. typically, post-operative care after a knee arthroplasty consists of compression (stockings), medications, rest, ice, elevation, physical therapy, and wound care. all of these treatments perform their role well, however, medications such opiates run the risk of addiction. an additional method of pain management such as heat application to the surrounding musculature warrants exploration. the goal of this study is to reduce the amount of pain, and improve the quality of life in post-operative patients. pain, stiffness, symptoms, quality of life and function of the knee will be evaluated utilizing patient-reported measures and range of motion. patients will be assessed using the knee injury and osteoarthritis outcome survey (koos jr), visual analogue scale (vas) and promis. patients will be given these surveys during their two and six week check-in with the surgeon. in addition to these patient-reported measures, the investigators will also be tracking range of motion (rom) and opioid usage. the data will then be collected via the patient's electronic health record, or by the researcher directly. the treatment group will be given a written order to apply heat to the quadriceps at least three times per day for 10-15 minutes each. this can be done in four hour increments or when patients symptoms begin to worsen. the patient will receive a rice sock for heat application. the control group will not be withheld from heat application, but will not be instructed to do so. the control group will instead follow the current standard of care as advised by the physician.


Eligibility criteria:
inclusion criteria: * patients undergoing a total knee arthroplasty ages 18 and older at saint alphonsus hospital and at the idaho clinic between the months of june-february, or until the estimated sample size (150) is reached. must be able to withstand heat to thigh. must consent to research. exclusion criteria: * anyone unable to give informed consent, pregnant individuals, children, or anyone whom the intervention may be harmful to.
rifaximin for functional dyspepsia

Conditions: Functional Dyspepsia

Summary: functional dyspepsia is a very common medical condition, which occurs in up to 30% of people in the community. however, results of current pharmacological treatment on functional dyspepsia are unsatisfactory. rifaximin is a minimally absorbed antibiotic that has been used in treatment of non-constipated irritable bowel syndrome (ibs). in particular, bloating and abdominal pain was improved by rifaximin treatment in this group of ibs patients. whilst there is considerable overlap in symptoms of functional dyspepsia and ibs, the investigators test whether rifaximin is also effective in curing post-prandial distress symptoms related to dyspepsia.

the aim of this study is to test the effects of rifaximin, a minimally absorbed antibiotics, on symptoms of patients with functional dyspepsia.

Eligibility criteria:
inclusion criteria: * non-ulcer dyspeptic patients who fulfill post-prandial distress syndrome according to the rome iii criteria * active dyspeptic symptom * normal upper endoscopy * urea breath test -ve or rapid urease test -ve * not typical gastroesophageal reflux or biliary colic symptoms, but presence of infrequent acid reflux is allowed exclusion criteria: * no active dyspeptic symptom * allergic to rifaximin * recent antibiotics use in the past 8 wk * recent ppi or h2ra in past 4 wk * on anti-coagulants, anti-convulsant or oral contraceptives * on nsaids, aspirin or clopidogrel * pregnancy or breast feeding * previous gastric surgery

Keywords: post-prandial distress syndrome
epidemiology of bacteremia at two tertiary icus in switzerland

Conditions: Bacteremia

Summary: the objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (icu inselspital bern and icu chuv lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.


Eligibility criteria:
inclusion criteria: patient has a positive blood culture with a pathogenic organism patient is critically ill at the time the blood culture was collected as defined by the following: 1. was treated at the icu/imc at the time of blood culture collection; 2. or has been admitted to icu/imc in the 48 hours after blood culture collection exclusion criteria: 1. patient has a single positive blood culture with a common contaminant organism: * coagulase negative staphylococci; * bacillus spp.; * corynebacterium spp.; * propionibacterium spp.; * aerococcus spp.; * micrococcus spp. 2. explicit documentation that the patient does not want to participate in any study
the effect of a new antioxidant combination (asted) on mild thyroid eye disease (ted)

Conditions: Thyroid Eye Disease

Summary: this randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as asted: 1. β- carotene (30 mg) 2. vit c (100 mg) 3. vit e (alpha-tocopherol acetate): 60-200 iu 4. calcium phosphate dihydrate (40 mg) 5. zinc oxide (4 mg, elemental) 6. copper gluconate (3.5 mg) 7. sodium selenite 23 mg= selenium 100 µg 8. nicotinamide (a form of vit.b3) (10 mg) in patients with mild thyroid eye disease according to eugogo classification. to be given twice a day.

1. to determine total eye score (nospecs severity score) before and after treatment in each of the three arms of the study and make a before - after as well as an inter-arm comparison. 2. to determine score of thyroid eye disease quality of life questionnaire (ted-qol) before and after treatment in each of the three arms of the study and make a before - after as well as an inter-arm comparison. 3. to determine clinical activity score (cas score) before and after treatment in each of the three arms of the study and make a before - after as well as an inter-arm comparison. 4. to determine serum thyroid auto-antibodies (anti thyroid peroxidase (tpo), anti-thyrogluboline) and thyroid function test (free t4, t3, and tsh) level before and after treatment in each of the three arms of the study and make a before - after as well as an inter-arm comparison. 5. to determine the rate of side effects in each arm and make a comparison.

Eligibility criteria:
inclusion criteria: 1. mild ted of less than 18 months duration (as recorded by the patient). 2. no active state (clinical activity score of less than 3). 3. no previous specific therapy for ted, except for local measures (artificial tear, head elevation, low salt diet). 4. euthyroidism as a result of remission after a course of antithyroid drug (atd) therapy, or euthyroidism for at least 2 months since commencing atd or after thyroidectomy, or euthyroidism for at least 6 months after radioiodine therapy. hypothyroid patients after thyroidectomy or radioiodine were replaced with levothyroxine. euthyroidism was defined as normal serum free thyroxine, total or free triiodothyronine concentrations, and thyrotropin (tsh) levels below 4 mu/liter patients were kept euthyroid for the whole duration of the study. 5. age 18-70 years. exclusion criteria: 1. ted severity of more than mild ted. 2. pregnancy 3. drug and/or alcohol abuse 4. severe concomitant illness 5. inability to comply with the study protocol 6. no informed consent 7. use of selenium- or vitamin/minerals-containing preparations in the last 3 months. 8. developing more severe ted in the course of the trial so that requires steroid treatment.

Keywords: antioxidant graves' ophthalmopathy thyroid eye disease severity score activity score quality of life
robot assisted upper limb neuro-rehabilitation

Conditions: Acute Stroke

Summary: our long term objectives are to understand the mechanisms of motor impairment following neurologic injury and to develop interventions to improve motor recovery. a series of complementary, overlapping clinical trials and development activities will validate and optimize the use of robot-assisted upper limb therapy for neuro rehabilitation. we have developed a robotic system that assists or resists elbow and shoulder movements in three dimensional space. in addition to unilateral exercise modes, a novel bimanual mode enables hemiparetic subjects to practice mirror image upper limb exercises.

randomized controlled clinical trial of the mirror image movement enabler (mime) robotic device for shoulder and elbow neurorehabilitation in subacute stroke patients. mime incorporates a puma 560 robot that applies forces to the paretic limb during unilateral and bilateral movements in three dimensions. robot-assisted treatment (bilateral, unilateral, and combined bilateral and unilateral) was compared with conventional therapy.

Eligibility criteria:
inclusion criteria: stroke patients exclusion criteria: unable to follow instructions; medically unstable.

Keywords: cerebrovascular hemiplegia robotics